In a filing, Nektar Therapeutics revealed its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $8788.0 on Aug 19 ’24. In the deal valued at $1.28 per share,6,866 shares were sold. As a result of this transaction, Zalevsky Jonathan now holds 250,804 shares worth roughly $0.26 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Wilson Mark Andrew sold 5,651 shares, generating $7,233 in total proceeds. Upon selling the shares at $1.28, the Chief Legal Officer now owns 225,263 shares.
Before that, ROBIN HOWARD W sold 14,881 shares. Nektar Therapeutics shares valued at $19,048 were divested by the President & CEO at a price of $1.28 per share. As a result of the transaction, ROBIN HOWARD W now holds 848,358 shares, worth roughly $0.87 million.
Piper Sandler initiated its Nektar Therapeutics [NKTR] rating to an Overweight in a research note published on November 04, 2024; the price target was $7. Rodman & Renshaw began covering NKTR with “Buy” recommendation on June 28, 2024.
Price Performance Review of NKTR
On Monday, Nektar Therapeutics [NASDAQ:NKTR] saw its stock fall -3.74% to $1.03. Over the last five days, the stock has lost -24.82%. Nektar Therapeutics shares have risen nearly 82.30% since the year began. Nevertheless, the stocks have risen 104.08% over the past one year. While a 52-week high of $1.93 was reached on 05/13/24, a 52-week low of $0.42 was recorded on 01/18/24. SMA at 50 days reached $1.2912, while 200 days put it at $1.2295.
Levels Of Support And Resistance For NKTR Stock
The 24-hour chart illustrates a support level at 1.0033, which if violated will result in even more drops to 0.9767. On the upside, there is a resistance level at 1.0733. A further resistance level may holdings at 1.1167. The Relative Strength Index (RSI) on the 14-day chart is 31.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1807, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.78%. Stochastics %K at 4.14% indicates the stock is a buying.
How much short interest is there in Nektar Therapeutics?
A steep rise in short interest was recorded in Nektar Therapeutics stocks on 2024-10-31, dropping by -2.08 million shares to a total of 5.23 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 7.31 million shares. There was a decline of -39.8%, which implies that there is a negative sentiment for the stock.
